title: VIM3-ARA C: an effective salvage regimen in refractory or recurrent aggressive non Hodgkin's lymphoma. A report on 18 cases.
abstract: Based on encouraging results of previous combination regimens, we used a combination of VM26, ifosfamide, methyl GAG, mitoxantrone (or adriamycin), high-dose (HD) methotrexate and HD Ara C to treat 18 patients with relapsed or refractory NHL. Front-line therapy had been in most of them a reinforced CHOP regimen. Twelve patients (67 per cent) responded: there were nine (50 per cent) partial responses (PR) and three (17 per cent) complete remissions (CR). Nine of these 12 responders were grafted (eight autologous, one allogeneic transplants), one relapsed before autograft could be performed and the two remaining patients were excluded from autograft because of positive bone marrow. Five of nine patients remained free of disease after 11+ to 27+ months. Response rate was higher in patients who relapsed 'off' therapy (2/3), but CR was also obtained in two refractory NHL and persisted for 11+ and 26+ months, suggesting that VIM3-ARA C was, at least partially, non-cross-resistant with front-line adriamycin-containing regimens.
authors.affiliation: Service des Maladies du Sang, Hopital C. Huriez, C.H.U., Lille, France.
authors.forename: B
authors.initials: B
authors.lastname: Dupriez
authors.forename: P
authors.initials: P
authors.lastname: Morel
authors.forename: P
authors.initials: P
authors.lastname: Fenaux
authors.forename: I
authors.initials: I
authors.lastname: Colcher-Plantier
authors.forename: T
authors.initials: T
authors.lastname: Facon
authors.forename: F
authors.initials: F
authors.lastname: Bauters
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D008776:Methylprednisolone Hemisuccinate / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D008935:Mitoguazone / Q000008:administration & dosage; D008942:Mitoxantrone / Q000008:administration & dosage / Q000627:therapeutic use; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D012097:Repressor Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D016879:Salvage Therapy; D015996:Survival Rate; D013713:Teniposide / Q000008:administration & dosage
chemical_list: D012097:Repressor Proteins; D003561:Cytarabine; D008776:Methylprednisolone Hemisuccinate; D013713:Teniposide; D011239:Prednisolone; D008942:Mitoxantrone; D008935:Mitoguazone; D007069:Ifosfamide; D008727:Methotrexate